Fat Nugs Magazine & Beard Bros Pharms Talk Reschedule: Views from Independent Cannabis Media
As we’ve all heard, seen and read by now, the DEA is taking an unprecedented step to reschedule cannabis as a Schedule III drug (maybe). Opinions as to whether this move by the Fed is good or bad are all over the place. So instead of just releasing another article that basically states the same things everyone has already read, as a team we wanted to share our personal opinions on the possible historical move and also get Bill and Jeff Levers of Beard Bros Pharms take on it.
Moldgate Retraction
Written By Nigel Despinasse
This is a errors, omissions, and retraction statement for the Moldgate article.
High at Any Cost: Weed Needs Ethical Laboratories and Official Testing Standards
Written By Daniel Crawford
State laws differ drastically when it comes to the variance of cannabis’ active ingredient, THC, as well as product sampling and testing methods. I know because I have worked in the Quality and Compliance realm for most of my professional career including Nevada, Virginia and Arizona’s Adult Use Cannabis markets. I have been the person responsible for compliance in each of those states.
Your purchase could be 20 percent higher or lower than the label claim in Arizona, 15 percent in Michigan and 10 percent in California. You don’t need a vivid imagination to be able to draw the line between inaccurate testing claims and the unpredictable-ness when it comes to dosing of patients. This is especially important for infrequent or new cannabis consumers who rely on accurate label claims for a consistent experience with their cannabis.